Eintrag weiter verarbeiten
Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , |
| In: | Journal of Clinical Oncology, 29, 2011, 2, S. 223-227 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Kloor, Matthias Voigt, Anita Y. Schackert, Hans K. Schirmacher, Peter von Knebel Doeberitz, Magnus Bläker, Hendrik Kloor, Matthias Voigt, Anita Y. Schackert, Hans K. Schirmacher, Peter von Knebel Doeberitz, Magnus Bläker, Hendrik |
|---|---|
| author |
Kloor, Matthias Voigt, Anita Y. Schackert, Hans K. Schirmacher, Peter von Knebel Doeberitz, Magnus Bläker, Hendrik |
| spellingShingle |
Kloor, Matthias Voigt, Anita Y. Schackert, Hans K. Schirmacher, Peter von Knebel Doeberitz, Magnus Bläker, Hendrik Journal of Clinical Oncology Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome Cancer Research Oncology |
| author_sort |
kloor, matthias |
| spelling |
Kloor, Matthias Voigt, Anita Y. Schackert, Hans K. Schirmacher, Peter von Knebel Doeberitz, Magnus Bläker, Hendrik 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2010.32.0820 <jats:sec><jats:title>Purpose</jats:title><jats:p> Lynch syndrome is an inherited tumor predisposition syndrome caused by germline mutations of DNA mismatch repair (MMR) genes, mainly MLH1 and MSH2. Recently, germline deletions affecting the epithelial cell adhesion molecule (EPCAM) gene located upstream of MSH2 were identified as a novel mutational mechanism causing Lynch syndrome by epigenetic inactivation of the respective MSH2 allele. Immunohistochemical analysis of MMR protein expression is a hallmark of Lynch syndrome diagnostics, but it cannot distinguish between EPCAM deletion carriers and MSH2 mutation carriers. We hypothesized that EPCAM protein expression might be altered in tumors from patients with a germline EPCAM deletion. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Immunohistochemistry was used to assess EPCAM expression in Lynch syndrome–associated MSH2-negative tumors (n = 26). Multiplex ligation-dependent probe amplification (MLPA) analysis was performed to detect germline deletions of the EPCAM and MSH2 gene loci. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> In four MSH2-negative tumors, a concomitant lack of EPCAM expression was detected. MLPA analysis revealed heterozygous EPCAM deletions in all patients with EPCAM-negative tumors. In contrast, EPCAM expression was positive in all cancers from patients with germline alterations affecting MSH2 but not EPCAM. Two EPCAM deletions were detected in patients with an EPCAM-positive tumor. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> These results indicate that loss of EPCAM protein expression is frequent in tumors from patients with EPCAM germline deletions. EPCAM immunohistochemistry therefore represents a promising novel tool for the identification of Lynch syndrome patients with EPCAM germline deletions. </jats:p></jats:sec> Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2010.32.0820 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMC4zMi4wODIw |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMC4zMi4wODIw |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Society of Clinical Oncology (ASCO), 2011 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2011 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
kloor2011analysisofepcamproteinexpressionindiagnosticsoflynchsyndrome |
| publishDateSort |
2011 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome |
| title_unstemmed |
Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome |
| title_full |
Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome |
| title_fullStr |
Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome |
| title_full_unstemmed |
Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome |
| title_short |
Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome |
| title_sort |
analysis of epcam protein expression in diagnostics of lynch syndrome |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2010.32.0820 |
| publishDate |
2011 |
| physical |
223-227 |
| description |
<jats:sec><jats:title>Purpose</jats:title><jats:p> Lynch syndrome is an inherited tumor predisposition syndrome caused by germline mutations of DNA mismatch repair (MMR) genes, mainly MLH1 and MSH2. Recently, germline deletions affecting the epithelial cell adhesion molecule (EPCAM) gene located upstream of MSH2 were identified as a novel mutational mechanism causing Lynch syndrome by epigenetic inactivation of the respective MSH2 allele. Immunohistochemical analysis of MMR protein expression is a hallmark of Lynch syndrome diagnostics, but it cannot distinguish between EPCAM deletion carriers and MSH2 mutation carriers. We hypothesized that EPCAM protein expression might be altered in tumors from patients with a germline EPCAM deletion. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Immunohistochemistry was used to assess EPCAM expression in Lynch syndrome–associated MSH2-negative tumors (n = 26). Multiplex ligation-dependent probe amplification (MLPA) analysis was performed to detect germline deletions of the EPCAM and MSH2 gene loci. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> In four MSH2-negative tumors, a concomitant lack of EPCAM expression was detected. MLPA analysis revealed heterozygous EPCAM deletions in all patients with EPCAM-negative tumors. In contrast, EPCAM expression was positive in all cancers from patients with germline alterations affecting MSH2 but not EPCAM. Two EPCAM deletions were detected in patients with an EPCAM-positive tumor. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> These results indicate that loss of EPCAM protein expression is frequent in tumors from patients with EPCAM germline deletions. EPCAM immunohistochemistry therefore represents a promising novel tool for the identification of Lynch syndrome patients with EPCAM germline deletions. </jats:p></jats:sec> |
| container_issue |
2 |
| container_start_page |
223 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
29 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792336975952347138 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:08:59.315Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Analysis+of+EPCAM+Protein+Expression+in+Diagnostics+of+Lynch+Syndrome&rft.date=2011-01-10&genre=article&issn=1527-7755&volume=29&issue=2&spage=223&epage=227&pages=223-227&jtitle=Journal+of+Clinical+Oncology&atitle=Analysis+of+EPCAM+Protein+Expression+in+Diagnostics+of+Lynch+Syndrome&aulast=Bl%C3%A4ker&aufirst=Hendrik&rft_id=info%3Adoi%2F10.1200%2Fjco.2010.32.0820&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792336975952347138 |
| author | Kloor, Matthias, Voigt, Anita Y., Schackert, Hans K., Schirmacher, Peter, von Knebel Doeberitz, Magnus, Bläker, Hendrik |
| author_facet | Kloor, Matthias, Voigt, Anita Y., Schackert, Hans K., Schirmacher, Peter, von Knebel Doeberitz, Magnus, Bläker, Hendrik, Kloor, Matthias, Voigt, Anita Y., Schackert, Hans K., Schirmacher, Peter, von Knebel Doeberitz, Magnus, Bläker, Hendrik |
| author_sort | kloor, matthias |
| container_issue | 2 |
| container_start_page | 223 |
| container_title | Journal of Clinical Oncology |
| container_volume | 29 |
| description | <jats:sec><jats:title>Purpose</jats:title><jats:p> Lynch syndrome is an inherited tumor predisposition syndrome caused by germline mutations of DNA mismatch repair (MMR) genes, mainly MLH1 and MSH2. Recently, germline deletions affecting the epithelial cell adhesion molecule (EPCAM) gene located upstream of MSH2 were identified as a novel mutational mechanism causing Lynch syndrome by epigenetic inactivation of the respective MSH2 allele. Immunohistochemical analysis of MMR protein expression is a hallmark of Lynch syndrome diagnostics, but it cannot distinguish between EPCAM deletion carriers and MSH2 mutation carriers. We hypothesized that EPCAM protein expression might be altered in tumors from patients with a germline EPCAM deletion. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Immunohistochemistry was used to assess EPCAM expression in Lynch syndrome–associated MSH2-negative tumors (n = 26). Multiplex ligation-dependent probe amplification (MLPA) analysis was performed to detect germline deletions of the EPCAM and MSH2 gene loci. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> In four MSH2-negative tumors, a concomitant lack of EPCAM expression was detected. MLPA analysis revealed heterozygous EPCAM deletions in all patients with EPCAM-negative tumors. In contrast, EPCAM expression was positive in all cancers from patients with germline alterations affecting MSH2 but not EPCAM. Two EPCAM deletions were detected in patients with an EPCAM-positive tumor. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> These results indicate that loss of EPCAM protein expression is frequent in tumors from patients with EPCAM germline deletions. EPCAM immunohistochemistry therefore represents a promising novel tool for the identification of Lynch syndrome patients with EPCAM germline deletions. </jats:p></jats:sec> |
| doi_str_mv | 10.1200/jco.2010.32.0820 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMC4zMi4wODIw |
| imprint | American Society of Clinical Oncology (ASCO), 2011 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2011 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T15:08:59.315Z |
| match_str | kloor2011analysisofepcamproteinexpressionindiagnosticsoflynchsyndrome |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 223-227 |
| publishDate | 2011 |
| publishDateSort | 2011 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Kloor, Matthias Voigt, Anita Y. Schackert, Hans K. Schirmacher, Peter von Knebel Doeberitz, Magnus Bläker, Hendrik 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2010.32.0820 <jats:sec><jats:title>Purpose</jats:title><jats:p> Lynch syndrome is an inherited tumor predisposition syndrome caused by germline mutations of DNA mismatch repair (MMR) genes, mainly MLH1 and MSH2. Recently, germline deletions affecting the epithelial cell adhesion molecule (EPCAM) gene located upstream of MSH2 were identified as a novel mutational mechanism causing Lynch syndrome by epigenetic inactivation of the respective MSH2 allele. Immunohistochemical analysis of MMR protein expression is a hallmark of Lynch syndrome diagnostics, but it cannot distinguish between EPCAM deletion carriers and MSH2 mutation carriers. We hypothesized that EPCAM protein expression might be altered in tumors from patients with a germline EPCAM deletion. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Immunohistochemistry was used to assess EPCAM expression in Lynch syndrome–associated MSH2-negative tumors (n = 26). Multiplex ligation-dependent probe amplification (MLPA) analysis was performed to detect germline deletions of the EPCAM and MSH2 gene loci. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> In four MSH2-negative tumors, a concomitant lack of EPCAM expression was detected. MLPA analysis revealed heterozygous EPCAM deletions in all patients with EPCAM-negative tumors. In contrast, EPCAM expression was positive in all cancers from patients with germline alterations affecting MSH2 but not EPCAM. Two EPCAM deletions were detected in patients with an EPCAM-positive tumor. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> These results indicate that loss of EPCAM protein expression is frequent in tumors from patients with EPCAM germline deletions. EPCAM immunohistochemistry therefore represents a promising novel tool for the identification of Lynch syndrome patients with EPCAM germline deletions. </jats:p></jats:sec> Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome Journal of Clinical Oncology |
| spellingShingle | Kloor, Matthias, Voigt, Anita Y., Schackert, Hans K., Schirmacher, Peter, von Knebel Doeberitz, Magnus, Bläker, Hendrik, Journal of Clinical Oncology, Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome, Cancer Research, Oncology |
| title | Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome |
| title_full | Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome |
| title_fullStr | Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome |
| title_full_unstemmed | Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome |
| title_short | Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome |
| title_sort | analysis of epcam protein expression in diagnostics of lynch syndrome |
| title_unstemmed | Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2010.32.0820 |